ZYBT ZYBT
Company Profile ↓Company Overview
ZYBT (ZYBT) is a publicly traded company listed on with a market capitalization of $65.40M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Trades at an undemanding P/E of 5.8.
Carries low leverage with a debt-to-equity ratio of 0.30.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $116.36M (-37.6% YoY); net profit $-69.78M.
- Trailing 12 Months Year-on-year growth — revenue -37.6%, earnings -717.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -23.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -23.53% |
| 1 Year: | -37.56% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -716.96% |
Stock Price Performance
| 1 Year: | -85.55% |
| 6 Months: | +80.39% |
| 3 Months: | +71.43% |
| 1 Month: | -11.54% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)42.59 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -23.5% CAGR over 5 years.
- Trading 85.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 260.27M | 211.65M | 186.36M | 116.36M |
| Cost of Revenue | - | 112.39M | 94.14M | 95.06M | 92.49M |
| Gross Profit | - | 147.88M | 117.51M | 91.30M | 23.87M |
| Operating Expenses | - | 81.79M | 69.87M | 74.12M | 92.12M |
| Operating Income | - | 66.09M | 47.64M | 17.17M | -68.25M |
| EBITDA | - | 85.55M | 72.10M | 42.60M | -42.52M |
| Interest Expense | - | 2.84M | 4.42M | 4.04M | 3.40M |
| Pretax Income | - | 63.91M | 43.76M | 14.39M | -71.87M |
| Tax Provision | - | 8.17M | 6.25M | 924.00K | 11.10M |
| Net Income | - | 46.73M | 31.46M | 11.31M | -69.78M |
| Diluted EPS | 0.83 | 0.99 | 0.67 | 0.24 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 519.67M | 499.89M | 493.25M | 436.47M |
| Current Assets | - | 214.31M | 189.24M | 177.57M | 137.42M |
| Cash & Equivalents | - | 9.75M | 15.07M | 18.60M | 50.33M |
| Inventory | - | 55.42M | 58.30M | 58.22M | 39.17M |
| Receivables | - | 102.90M | 74.17M | 59.56M | 18.48M |
| Total Liabilities | - | 162.81M | 160.62M | 140.71M | 129.76M |
| Current Liabilities | - | 152.23M | 150.23M | 135.91M | 120.48M |
| Long Term Debt | - | 9.99M | 9.99M | 4.80M | 8.85M |
| Total Debt | - | 64.88M | 89.85M | 86.43M | 75.08M |
| Total Equity | - | 296.50M | 272.85M | 283.96M | 249.85M |
| Shares Outstanding | - | 47.17M | 47.17M | 47.17M | 47.39M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 17.34M | 48.18M | 41.05M | 13.33M |
| Investing Cash Flow | - | -27.33M | -11.77M | -27.66M | -12.63M |
| Financing Cash Flow | - | 13.46M | -18.98M | -22.13M | 32.31M |
| Capital Expenditure | - | -27.33M | -11.60M | -27.77M | -12.63M |
| Free Cash Flow | - | -9.99M | 36.58M | 13.27M | 703.00K |
| Net Change in Cash | - | 3.46M | 17.44M | -8.75M | 33.01M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 56.8% | 55.5% | 49.0% | 20.5% |
| Operating Margin % | - | 25.4% | 22.5% | 9.2% | -58.7% |
| Net Margin % | - | 18.0% | 14.9% | 6.1% | -60.0% |
| ROE % | - | 15.8% | 11.5% | 4.0% | -27.9% |
| ROCE % | - | 18.0% | 13.6% | 4.8% | -21.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ZYBT
Zhengye Biotechnology Says No Material Events Behind Unusual Trading Activity (NASDAQ:ZYBT)
The company issued a statement after a sharp increase in trading volume, saying it is unaware of any undisclosed developments that would explain the recent market activity. Key Investor TakeawaysZhengye Biotechnology (NASDAQ:ZYBT) said it i…
Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Jilin, China, June 04, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterin…
Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure
Jilin, China, April 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veteri…
Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity
Jilin, China, July 21, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterin…
Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirement
Jilin, China, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterin…
Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results
Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines…
ZYBT — Frequently Asked Questions
What is the current share price of ZYBT?
As of 2026-09-16 18:39 PDT, ZYBT trades at $1.38 on NASDAQ/NYSE. Its 52-week range is $0.65 to $9.55.
What is the market capitalisation of ZYBT?
ZYBT has a market capitalisation of $65.40M on NASDAQ/NYSE.
What is the P/E ratio of ZYBT?
ZYBT trades at a trailing price-to-earnings (P/E) ratio of 5.75. Its price-to-book (P/B) ratio is 0.26.
What is the return on equity (ROE) of ZYBT?
ZYBT has a return on equity (ROE) of -27.93%. Its return on capital employed (ROCE) is -21.60%.
Is ZYBT a good stock to buy?
This page provides a data-driven analysis of ZYBT, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.